Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
The company enjoys a big share of China’s anti-tetanus market but is looking to diversify into antidotes for rabies and snake bites to drive future growth Key Takeaways: The company…
WuXi group wrestles with uncertainty over pharma tariffs
Drugs services giant WuXi AppTec cashed in a stake in Wuxi XDC to soften the blow from a first round of Trump tariffs, as the pharma sector braces for another…
Neautus looks outward to boost its traditional medicine story
The maker of traditional Chinese medicines has applied for a Hong Kong IPO after abandoning two listing attempts on China’s domestic A-share market Key Takeaways: Neautus has applied to list…
Joinn Labs undermined by AI as FDA phases out animal drug testing
The outsourced clinical research services provider’s shares tumbled after the U.S. drug regulator announced a new approach to drug testing Key Takeaways: Joinn Labs’ shares fell on heavy trading as…
Investors cheer Akeso’s revenue milestone, even as it returns to the red
The drugmaker’s shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso’s drug sales rose 25%…
Dispute over Covid vaccines casts doubt on Clover Bio recovery
The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines Key Takeaways: The Gavi international…
CARsgen seeks cell therapy breakthrough but stays in the red for now
The developer of specialized cancer treatments is shifting from costly personalized therapy to more standardized options, but at the price of short-term financial pain Key Takeaways: The company launched its…
Recent Articles
BRIEF: CATL passes Hong Kong listing hearing
300750.SHE
BRIEF: Ant Group eyes Hong Kong listing for overseas unit
9988.HK
BABA.US
RELATED ARTICLES
-
Ruanyun soars as China edtechs learn to live in new environment
RYET.US - Jiaxin mines Hong Kong, Kazakhstan for IPO funds
-
Singapore business dynasty has Vitasoy in its sights
0345.HK 0083.HK
- Shanghai family feud ties up $1 billion in property, offers lesson for investors
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Mao Geping’s Hong Kong IPO gets lift from regulatory nod
-
Xiaocaiyuan sets the table for Hong Kong IPO. But is the timing right?
0999.HK
